PE20090307A1 - Derivados de 7-alquinil-1,8-naftiridonas como agentes inhibidores de vegfr-3 - Google Patents
Derivados de 7-alquinil-1,8-naftiridonas como agentes inhibidores de vegfr-3Info
- Publication number
- PE20090307A1 PE20090307A1 PE2008000997A PE2008000997A PE20090307A1 PE 20090307 A1 PE20090307 A1 PE 20090307A1 PE 2008000997 A PE2008000997 A PE 2008000997A PE 2008000997 A PE2008000997 A PE 2008000997A PE 20090307 A1 PE20090307 A1 PE 20090307A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- oxo
- vegfr
- naphthyridine
- carboxamide
- Prior art date
Links
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 title abstract 2
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 1-HYDROXYCYCLOPENTYL Chemical class 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- XEHVFKKSDRMODV-UHFFFAOYSA-N ethynyl Chemical compound C#[C] XEHVFKKSDRMODV-UHFFFAOYSA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
REFERIDA A UN DERIVADO DE NAFTIRIDONA DE FORMULA (I), DONDE R1 Y R2 SON H, ALQUILO C1-C7, CO-ALQUILO C1-C7, FENILO, ENTRE OTROS; R3 ES ALQUILO C1-C7, -(CH2)n-HETEROCICLO, DONDE n ES UN ENTERO DE 0 A 3 Y EL HETEROCICLO COMPRENDE DE 4 A 8 MIEMBROS Y ESTA OPCIONALMENTE SUSTITUIDO CON UN GRUPO OXO, ENTRE OTROS; R4 ES H, ALQUILO C1-C4, ALCOXI C1-C4. SON COMPUESTOS PREFERIDOS: 2-AMINO-1-ETIL-7-(3-HIDROXI-3-METILBUT-1-IN-1-IL)-N-METIL-4-OXO-1,4-DIHIDRO-1,8-NAFTIRIDINA-3-CARBOXAMIDA, (Œ)-2-AMINO-1-ETIL-7-[(1-HIDROXICICLOPENTIL)ETINIL]-N-METIL-4-OXO-1,4-DIHIDRO-1,8-NAFTIRIDINA-3-CARBOXAMIDA, (Œ)-2-AMINO-1-ETIL-7-(3-HIDROXI-4-METOXI-3-METILBUT-1-IN-1-IL)-N-METIL-4-OXO-1,4-DIHIDRO-1,8-NAFTIRIDINA-3-CARBOXAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD INHIBIDORA SOBRE LA ENZIMA VEGFR-3 Y SON UTILES EN EL TRATAMIENTO DE ARTROSIS, ENFERMEDADES AUTOINMUNES, NEFROPATIAS, ENTRE OTRAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0704192A FR2917412B1 (fr) | 2007-06-13 | 2007-06-13 | Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090307A1 true PE20090307A1 (es) | 2009-04-20 |
Family
ID=38870275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008000997A PE20090307A1 (es) | 2007-06-13 | 2008-06-11 | Derivados de 7-alquinil-1,8-naftiridonas como agentes inhibidores de vegfr-3 |
Country Status (45)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2917413B1 (fr) * | 2007-06-13 | 2009-08-21 | Sanofi Aventis Sa | Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique |
| FR2933700B1 (fr) | 2008-07-08 | 2010-07-30 | Sanofi Aventis | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
| FR2952934B1 (fr) | 2009-11-23 | 2012-06-22 | Sanofi Aventis | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
| FR2954943B1 (fr) * | 2010-01-07 | 2013-03-01 | Sanofi Aventis | Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique |
| FR2955109B1 (fr) * | 2010-01-08 | 2012-09-07 | Sanofi Aventis | Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique |
| FR2965263A1 (fr) | 2010-09-24 | 2012-03-30 | Sanofi Aventis | Derives de thienopyridine nicotinamide, leur preparation et leur application en therapeutique |
| EP2524915A1 (en) | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
| JP5748210B2 (ja) * | 2011-05-26 | 2015-07-15 | 日本化薬株式会社 | 複素環化合物の製造方法 |
| KR102068860B1 (ko) * | 2012-07-17 | 2020-01-21 | 사노피 | Vegfr-3 저해제의 간세포암 치료를 위한 용도 |
| CN108558869B (zh) * | 2018-05-10 | 2019-04-09 | 西安培华学院 | 用于治疗肝癌的化合物及其制剂 |
| CN110981869A (zh) * | 2019-12-10 | 2020-04-10 | 天津科技大学 | 一种1,8-双氮杂色酮的合成方法及其在抗糖尿病药物中的应用 |
| CN116509854A (zh) * | 2023-04-26 | 2023-08-01 | 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） | 一种萘啶酮衍生物的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9800921A (es) * | 1995-08-02 | 1998-05-31 | Chirotech Technology Ltd | Quinolonas y su uso terapeutico. |
| EP0978516A4 (en) * | 1998-01-29 | 2001-01-10 | Suntory Ltd | 1-CYCLOALKYL-1,8-NAPHTHYRIDINE-4-ONE DERIVATIVES HAVING PHOSPHODIESTERASE IV INHIBITING ACTIVITY |
| ES2247325T3 (es) * | 2001-05-24 | 2006-03-01 | MERCK FROSST CANADA & CO. | Inhibidores de 1-biaril-1,8-naftiridin-4-ona fosfodiesterasa-4. |
| US20070254877A1 (en) | 2004-06-02 | 2007-11-01 | Takada Pharmaceutical Company Limited | Indole Derivative and Use for Treatment of Cancer |
| FR2917413B1 (fr) * | 2007-06-13 | 2009-08-21 | Sanofi Aventis Sa | Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique |
-
2007
- 2007-06-13 FR FR0704192A patent/FR2917412B1/fr not_active Expired - Fee Related
-
2008
- 2008-05-27 PA PA20088781701A patent/PA8781701A1/es unknown
- 2008-06-11 KR KR1020097025888A patent/KR101517636B1/ko active Active
- 2008-06-11 PE PE2008000997A patent/PE20090307A1/es not_active Application Discontinuation
- 2008-06-11 ME MEP-2009-346A patent/ME00961B/me unknown
- 2008-06-11 AU AU2008274099A patent/AU2008274099B2/en active Active
- 2008-06-11 PT PT08826268T patent/PT2158201E/pt unknown
- 2008-06-11 AP AP2010005099A patent/AP2590A/xx active
- 2008-06-11 SI SI200830273T patent/SI2158201T1/sl unknown
- 2008-06-11 WO PCT/FR2008/000793 patent/WO2009007535A2/fr active Application Filing
- 2008-06-11 ES ES08826268T patent/ES2365073T3/es active Active
- 2008-06-11 EP EP08826268A patent/EP2158201B1/fr active Active
- 2008-06-11 MY MYPI20095271A patent/MY157754A/en unknown
- 2008-06-11 EA EA201070009A patent/EA016939B1/ru not_active IP Right Cessation
- 2008-06-11 CA CA2690337A patent/CA2690337C/fr active Active
- 2008-06-11 UA UAA201000231A patent/UA96994C2/ru unknown
- 2008-06-11 JP JP2010511680A patent/JP5343072B2/ja active Active
- 2008-06-11 DE DE602008006188T patent/DE602008006188D1/de active Active
- 2008-06-11 BR BRPI0814035-9A patent/BRPI0814035B1/pt active IP Right Grant
- 2008-06-11 DK DK08826268.8T patent/DK2158201T3/da active
- 2008-06-11 AT AT08826268T patent/ATE505469T1/de active
- 2008-06-11 MX MX2009013515A patent/MX2009013515A/es active IP Right Grant
- 2008-06-11 PL PL08826268T patent/PL2158201T3/pl unknown
- 2008-06-11 TW TW097121818A patent/TWI405762B/zh not_active IP Right Cessation
- 2008-06-11 NZ NZ581839A patent/NZ581839A/en not_active IP Right Cessation
- 2008-06-11 CN CN200880020027XA patent/CN101679427B/zh active Active
- 2008-06-11 AR ARP080102477A patent/AR066954A1/es unknown
- 2008-06-12 JO JO2008277A patent/JO2682B1/en active
- 2008-06-13 CL CL2008001775A patent/CL2008001775A1/es unknown
- 2008-06-13 UY UY31152A patent/UY31152A1/es not_active Application Discontinuation
-
2009
- 2009-11-18 TN TNP2009000483A patent/TN2009000483A1/fr unknown
- 2009-11-25 DO DO2009000264A patent/DOP2009000264A/es unknown
- 2009-12-01 GT GT200900309A patent/GT200900309A/es unknown
- 2009-12-03 NI NI200900211A patent/NI200900211A/es unknown
- 2009-12-03 SV SV2009003429A patent/SV2009003429A/es not_active Application Discontinuation
- 2009-12-04 US US12/631,122 patent/US8470847B2/en active Active
- 2009-12-09 EC EC2009009791A patent/ECSP099791A/es unknown
- 2009-12-09 IL IL202640A patent/IL202640A/en not_active IP Right Cessation
- 2009-12-10 CR CR11157A patent/CR11157A/es unknown
- 2009-12-10 CO CO09141427A patent/CO6150150A2/es unknown
- 2009-12-11 HN HN2009003402A patent/HN2009003402A/es unknown
-
2010
- 2010-01-12 MA MA32508A patent/MA31567B1/fr unknown
- 2010-08-26 HK HK10108139.3A patent/HK1141790A1/xx not_active IP Right Cessation
-
2011
- 2011-06-16 CY CY20111100571T patent/CY1111631T1/el unknown
- 2011-07-11 HR HR20110515T patent/HRP20110515T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090307A1 (es) | Derivados de 7-alquinil-1,8-naftiridonas como agentes inhibidores de vegfr-3 | |
| AR054790A1 (es) | Metodos para el tratamiento de disfuncion sexual | |
| PE20090189A1 (es) | Derivados de aza-piridopirimidinona como agonistas de hm74a | |
| PE20110547A1 (es) | Compuestos de isoindolina con actividad anticancerigena | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| PE20170247A1 (es) | Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1 | |
| TW200745058A (en) | MMP-13 selective inhibitors | |
| PE20090904A1 (es) | ARILOXAZOLES SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE ADENOSINA A1 Y/O A2b | |
| AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
| ECSP067013A (es) | 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4 | |
| CO6270320A2 (es) | Derivados de piperidina utiles como antagonistas del receptor orexina | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| ES2556350T3 (es) | Inhibidores de indazol de la vía de señalización de Wnt y sus usos terapéuticos | |
| PE20070833A1 (es) | Compuestos de pirimidinil benzotiofeno | |
| PE20080409A1 (es) | Compuestos que modulan en el receptor cb2 | |
| PE20091414A1 (es) | FURO [3,2-c] PIRIDINA Y TIENO [3,2-c] PIRIDINAS | |
| RS53679B1 (en) | FURAZANOBENZIMIDAZOLES AS PROGRAMS FOR THE TREATMENT OF NEOPLASTIC OR AUTOIMMUNE DISEASES | |
| PE20070212A1 (es) | Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen | |
| AR072726A1 (es) | Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c | |
| MA30756B1 (fr) | Derives de cinnamoyl-piperazine et leur utilisation comme antagonistes par-1 | |
| MX2011011281A (es) | Compuesto de carbinol que tiene un enlazante heterociclico. | |
| AR064424A1 (es) | Derivados sustituidos de 1-oxo-ftalazinas y 1-oxo-pirido-piridazinas,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar enfermedades inflamatorias y alergicas del tracto respiratorio. | |
| EA201070010A1 (ru) | Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии | |
| AR071619A1 (es) | Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias y composiciones farmaceuticas que los contienen. | |
| AR047466A1 (es) | Compuestos derivados de 3h - imidazo[4,5 - b]piridina con actividad inhibidora de quinasa, composiciones farmacéuticas que los contienen como principio activo y su uso en la fabricacion de un medicamento para el tratatmiento de neoplasmas susceptibles. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |